EMA/330461/2013

European Medicines Agency decision

P/0138/2013

of 21 June 2013

on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid) (EMEA-000115-PIP02-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0138/2013

of 21 June 2013

on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid) (EMEA-000115-PIP02-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/106/2011 issued on 4 May 2011,

Having regard to the application submitted by PTC Therapeutics, Limited on 22 February 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 May 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid), granules for oral suspension, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to PTC Therapeutics, Limited, 16 Great Queen Street, Covent Garden WC2B 5AH – London, United Kingdom.

Done at London, 21 June 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/134699/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000115-PIP02-09-M01

Scope of the application

Active substance(s):

Ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid)

Condition(s):

Treatment of cystic fibrosis

Pharmaceutical form(s):

Granules for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

PTC Therapeutics, Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, PTC Therapeutics, Limited submitted to the European Medicines Agency on 22 February 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/106/2011 issued on 4 May 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 20 March 2013.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 17 May 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of cystic fibrosis

The waiver applies to:

- neonates from birth to less than 28 days of age;
- granules for oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of cystic fibrosis

2.1.1. Indication(s) targeted by the PIP

Treatment of cystic fibrosis due to nonsense mutation (nmCF)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Children from 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Granules for oral suspension

2.1.4. Measures

Area	Number of studies	Description
Quality	1	Measure 1: Age appropriate formulation and dosing device that allows accurate dosing for children weighing less than 20 kg.
Non-clinical	3	Measure 2: 7-day tolerability and pharmacokinetic study of ataluren in neonatal Beagle dogs Measure 3: 28-day dose range finding juvenile toxicology and toxicokinetic Study of ataluren in Beagle Dogs Measure 4: 3-Month Juvenile Toxicology and Toxicokinetic Study of ataluren in Beagle Dogs with a 3-Month Recovery Period

Clinical	5	Measure 5: Open-label, randomized, dose-ranging, challenge-dechallenge-rechallenge evaluation of pharmacodynamic (PD) activity, safety, and pharmacokinetics of ataluren. Measure 6: Randomised, double-blind, placebo-controlled study to evaluate efficacy of ataluren adult and paediatric nmCF patients, ≥6 years of age Measure 7: Open-label extension study to evaluate safety of ataluren in adult and paediatric nmCF patients, ≥6 years of age. Measure 8: Open label, multiple dose trial to evaluate the pharmacokinetics (PK), safety and pharmacodynamic (PD) effect of ataluren in paediatric patients with nmCF aged from 2 to less than 6 years. Measure 9: Open label, multiple dose trial to evaluate the pharmacokinetics (PK) and safety of ataluren in paediatric patients with nmCF aged from 28 days to less than 23 months.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By December 2016.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes.